BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. BeiGene, Ltd. has a strategic collaboration with Shoreline Biosciences, Inc. to develop and commercialize a portfolio of NK-based cell therapeutics. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.
IPO Year: 2016
Exchange: NASDAQ
Website: beigene.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/6/2024 | $185.00 | Overweight | JP Morgan |
9/12/2023 | $259.00 | Outperform | Macquarie |
8/17/2023 | $287.00 | Buy | Jefferies |
7/17/2023 | $275.00 | Buy | Citigroup |
6/30/2023 | $335.00 → $196.00 | Outperform → Mkt Perform | Bernstein |
1/12/2023 | $308.00 | Buy | Daiwa Securities |
10/13/2022 | $205.00 | Neutral → Buy | Guggenheim |
10/13/2022 | $177.00 → $200.00 | Mkt Perform → Outperform | SVB Leerink |
8/9/2022 | $296.00 | Overweight | JP Morgan |
3/17/2022 | $300.00 → $177.00 | Outperform → Mkt Perform | SVB Leerink |
8-K - BeiGene, Ltd. (0001651308) (Filer)
144 - BeiGene, Ltd. (0001651308) (Subject)
S-4 - BeiGene, Ltd. (0001651308) (Filer)
10-Q - BeiGene, Ltd. (0001651308) (Filer)
8-K - BeiGene, Ltd. (0001651308) (Filer)
8-K - BeiGene, Ltd. (0001651308) (Filer)
144 - BeiGene, Ltd. (0001651308) (Subject)
144 - BeiGene, Ltd. (0001651308) (Subject)
S-8 - BeiGene, Ltd. (0001651308) (Filer)
8-K - BeiGene, Ltd. (0001651308) (Filer)
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. "We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "Matt's management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies." Mr. Shaulis is a global commercial executive with ov
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, with a fireside chat at 10 a.m. EDT. The live webcast of this event can be accessed from the investors section of BeiGene's website at http://ir.beigene.com, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 180 days following the event. About BeiGene BeiGene is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio,
Designation supported by promising safety and efficacy data from Phase 1/2 study in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BGB-16673, an orally available investigational Bruton's tyrosine kinase (BTK) targeting chimeric degradation activation compound (CDAC), for adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have been previously treated with a
Generated total revenues of $929 million, an increase of 56% from the prior-year period; reduced GAAP operating loss and achieved non-GAAP operating income Strengthened hematology leadership with global BRUKINSA revenues of $637 million, an increase of 107% from the prior-year period; advanced pivotal programs for BCL2 inhibitor sonrotoclax and BTK-targeted degrader BGB-16673 Advanced innovative solid tumor pipeline of more than 15 investigational molecules, including ADCs, multispecific antibodies, and targeted therapies for lung, breast, and gastrointestinal cancers Strengthened global presence with opening of $800 million, 42-acre flagship U.S. biologics manufacturing facility
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the opening of its flagship U.S. facility in Hopewell, N.J., at the Princeton West Innovation Campus, which houses state-of-the-art biologics manufacturing capabilities and a clinical research and development center that further bolster the Company's differentiated model as an oncology innovator. BeiGene has more than 30 molecules at clinical or commercial stage, and the 42-acre facility provides flex
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the Company through August to support the transition. "We are thrilled to welcome Aaron amid a transformational year for BeiGene as we became a top 15 global oncology innovator by revenue with sustained progress to profitability and one of the most prolific and innovative pipelines in our industry including a plan to have at least 10 new molecular entities this year. Aaron's financial leadership and impr
Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest promising efficacy and tolerability Safety profile was consistent with results of prior BRUKINSA studies BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain in an oral session (Abstract S160). The presentation will feature data from arm D of SEQUOIA evaluating BRUKINSA in combination w
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 with a fireside chat at 1:20 pm EDT. Live webcast of this event can be accessed from the investors section of BeiGene's website at http://ir.beigene.com, https://hkexir.beigene.com/, https://sseir.beigene.com/. Archived replay will be available for 180 days following the event. About BeiGene BeiGene is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfo
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a clinical supply agreement with BeiGene, Ltd. (NASDAQ:BGNE) ("BeiGene") to evaluate the safety and efficacy of Bria-OTS™, BriaCell's next generation immunotherapy, in combination with BeiGene's anti-PD-1 antibody, tislelizumab, for the treatment
New network meta-analysis demonstrates favorable progression-free survival for patients treated with BRUKINSA vs other BTKi's Analysis of Kaiser Permanente database shows BRUKINSA effective and generally well tolerated, including in patients switching to BRUKINSA from ibrutinib ALPINE post hoc analysis shows less frequent initiation of new antihypertensives or a new class of antihypertensives in patients treated with BRUKINSA vs. ibrutinib BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the presentation of new analyses for BRUKINSA® (zanubrutinib) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 -
JP Morgan resumed coverage of BeiGene with a rating of Overweight and set a new price target of $185.00
Macquarie initiated coverage of BeiGene with a rating of Outperform and set a new price target of $259.00
Jefferies initiated coverage of BeiGene with a rating of Buy and set a new price target of $287.00
Citigroup initiated coverage of BeiGene with a rating of Buy and set a new price target of $275.00
Bernstein downgraded BeiGene from Outperform to Mkt Perform and set a new price target of $196.00 from $335.00 previously
Daiwa Securities initiated coverage of BeiGene with a rating of Buy and set a new price target of $308.00
Guggenheim upgraded BeiGene from Neutral to Buy and set a new price target of $205.00
SVB Leerink upgraded BeiGene from Mkt Perform to Outperform and set a new price target of $200.00 from $177.00 previously
JP Morgan resumed coverage of BeiGene with a rating of Overweight and set a new price target of $296.00
SVB Leerink downgraded BeiGene from Outperform to Mkt Perform and set a new price target of $177.00 from $300.00 previously
B of A Securities analyst David Li maintains BeiGene (NASDAQ:BGNE) with a Neutral and lowers the price target from $180 to $152.5.
These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio? Walgreens Boots Alliance, Inc. (NASDAQ:WBA) shares tumbled 24.12% after the company reported mixed Q3 earnings and lowered 2024 guidance below consensus estimates. Analysts cut the price forecasts on the stock. Floor & Decor Holdings, Inc. (NYSE:FND) shares lost 13.41%, possibly in reaction to worse-than-expected May Pending Home Sales economic data. Moderna, Inc. (NASDAQ:MRNA) shares fell 11.76% after the company’s RSV vaccine showed 50% efficacy. Birkenstock Holding Plc (NYSE:BIRK) stock declined 10.86% after the company announced an offering of up to 14 million ordinary sh
Sunday, Nurix Therapeutics Inc (NASDAQ:NRIX) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Bruton’s tyrosine kinase (BTK). BTK inhibitors have become a major commercial class, with drugs such as BeiGene Inc’s (NASDAQ:BGNE) Brukinsa (Zanubrutinib), Eli Lilly And Co’s (NYSE:LLY) Jaypirca (Pirtobrutinib), Johnson & Johnson’s (NYSE:JNJ) Imbruvica (Ibrutinib), and AstraZeneca Plc’s (NASDAQ:AZN) Calquence (Acalabrutinib). NX-5948 is being evaluated in an ongoing Phase 1a/b trial in adults with relapsed or refractory B-cell malignancies, including CLL and non-Hodgkin lymphoma (NHL). The data presented at EHA include safety findings for
BeiGene, Ltd. a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain in an oral session. The presentation will feature data from arm D of SEQUOIA evaluating BRUKINSA in combination with venetoclax in treatment-naïve (TN) patients with high-risk chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) with del(17p) and/or TP53 mutation. The preliminary data demonstrate that in the 65 response-evaluable patients treated with the combination, the overall response rate (ORR) was 100%, and the rate of complete response (CR) pl
These 10 large-cap stocks were the worst performers last week. Are they in your portfolio? National Grid Transco (NYSE:NGG) decreased 17.1% after the company reported an equity raise of £7 billion and a year-over-year decrease in full-year revenue results. James Hardie Industries Plc (NYSE:JHX) shares declined 14.4% after the company reported worse-than-expected Q4 financial results. KE Holdings Inc (NYSE:BEKE) shares lost 14% in the last week after the company reported Q1 financial results. JD.Com, Inc. (NASDAQ:JD) stock tumbled 13.70% after the company announced interim Q1 results and proposed an offering of $1.5 billion convertible senior notes. XP Inc. (NASDAQ:XP) shares
The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton's tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). "At this year's ASCO, multiple presentations continue to add to our extensive body of evidence demonstrating BRUKINSA's uniquely differentiated clinical profile," Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. "These new analyses, which highlight improved PFS and response rates and a low usage of antihypertensive medicines, provide valuable insights for oncologists to consider when making treatment decisions for their patients with CLL an
BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support Investigational New Drug filing BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global biotechnology company, and DualityBio, a next-generation ADC company, today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors. "With one of the industry's leading global oncology research teams, we are investing in highly impactful therapeutic modalities such as ADCs that complement our dynam
Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual Meeting BRUKINSA demonstrated superiority to IMBRUVICA in both PFS and Overall Response Rate with fewer cardiac events BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))) a global biotechnology company, today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA® as compared to IMBRUVICA® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160))), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it will host an investor conference call and webcast on Wednesday, August 25, 2021, at 9:30 a.m. ET to discuss the Company's early development pipeline and research. A live webcast of the conference call can be accessed from the investors section of BeiGene's website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available after the event for 90 days. About BeiGene BeiGene is a global, science-driven biotechnology company
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in South Korea in a pivotal, single-arm clinical trial of zanidatamab (formerly ZW25) monotherapy in patients with advanced or metastatic HER2-amplified biliary tract cancer (BTC). Zymeworks will receive a US$10 million payment under its collaboration with BeiGene as a result of the achievement of this development milestone. “Patients with biliary tract cancer generally have a poor prognosis and few treatment options,” said Diana Hausman, M.D., C
THOUSAND OAKS, Calif., Nov. 30, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, Dec. 5-8, 2020. Amgen will present updated data from its bispecific T cell engager (BiTE®) portfolio in two oral presentations. Data include the first safety and efficacy findings from the ongoing Phase 1 dose escalation study of AMG 701, an investigational half-life extended BiTE immuno-oncology therapy targeting B-cell maturation antigen (BCMA), in patients with heavily pre-treated relapsed/refractory multiple myel
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13D/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13G/A - BeiGene, Ltd. (0001651308) (Subject)
SC 13G - BeiGene, Ltd. (0001651308) (Subject)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
3 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
4 - BeiGene, Ltd. (0001651308) (Issuer)
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. "We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "Matt's management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies." Mr. Shaulis is a global commercial executive with ov
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the Company through August to support the transition. "We are thrilled to welcome Aaron amid a transformational year for BeiGene as we became a top 15 global oncology innovator by revenue with sustained progress to profitability and one of the most prolific and innovative pipelines in our industry including a plan to have at least 10 new molecular entities this year. Aaron's financial leadership and impr
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt will join the audit committee of the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123611725/en/Olivier Brandicourt, M.D. (Photo: Business Wire) Dr. Brandicourt replaces Thomas Malley, who has served on the Board since 2016. "Dr. Brandicourt brings a wealth of global experience as we expand the perspective of BeiGene's Board of Directors to include deep expertise in leading multinational growth companies, spearheading lau
Pryor will spearhead BeiGene's efforts to pair global health equity with diversity and inclusion BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230330005198/en/Julius Pryor III (Photo: Business Wire) Mr. Pryor has more than 30 years of experience in Diversity, Equity, Inclusion & Belonging (DEI&B) efforts, having successfully built transformational DEI&B programs for biotechnology companies, as well as global consumer
BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology biotechnology company focused on developing and commercializing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Chan Lee as General Counsel, effective July 18, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005323/en/Chan Lee, General Counsel, BeiGene (Photo: Business Wire) Mr. Lee joins BeiGene from Sanofi and will bring his significant expertise leading legal functions in the biopharma industry to overseeing legal, compliance, intellectual property and related m
-- Jane Huang, M.D., appointed as independent director -- -- Sanjay Trehan joins as SVP of Business Development -- -- Gretchen Bain, Ph.D., promoted to SVP of Biology -- 858 Therapeutics today announced the strengthening of its board of directors and leadership team in preparation for its next stage of growth. To support the advancement of 858 Therapeutics' portfolio of small molecule therapeutics directed against oncology targets, the company has named Jane Huang, M.D., as an independent director on the company's Board. In addition, 858 Therapeutics has appointed Sanjay Trehan as SVP of Business Development and has promoted Gretchen Bain, Ph.D., to SVP of Biology. The company debuted i
Industry Leaders Lend Scientific and Clinical Expertise to Several Board Committees BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the appointment of Margaret Dugan, M.D., and Alessandro Riva, M.D., to its Board of Directors. Dr. Dugan will join the scientific advisory committee and Dr. Riva will join the nominating and corporate governance, and scientific advisory committees of the board. In addition, Jing-Shyh (Sam) Su will be stepping down from BeiGene's board of directors after serving for almost fo
NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders' established experience in global clinical development and especially with new technologies will be instrumental as we further advance our ongoing clinical trials and continue to expand our rare disease pipeline of novel therapeut